The company announced the 50 per cent acquisition of Mumbai-based Sterling Biotech Ltd. Zydus will be taking over Sterling Biotech's API or Active Pharmaceutical Ingredients Business. Zydus Makes ...

Michael Gilman, biotech entrepreneur: I am — as a parent and grandparent, rather than a life science executive — considerably ...

A Dallas-based biotech company has nearly completed its reconstruction of the Tasmanian tiger just two years into its de-extinction project. The last known thylacine, commonly referred to as the ...

Sterling Bay is looking to offload a biotech property on Chicago’s North Side, as its life sciences real estate holdings and its Lincoln Yards project face setbacks. The Chicago-based firm ...

Allison DeAngelis, who covers biotech startups and venture capital, is also the author of STAT’s annual report “Ranking Biotech’s Top Venture Capital Firms.” Biotech investors have been ...

Lincoln Yards developer Sterling Bay plans to sell the biotech center near the North Side development as it faces challenges in the biosciences sector and its own plans for the area. The Lincoln ...

A great performance over the last 12 months has pushed our writer to buy more of a very exciting investment trust for his Stocks and Shares ISA. Paul Summers explains why.

Hello! Hope you had a restful and reflective Indigenous Peoples’ Day. Today, we talk about how the autoimmune disease space is hotter than ever, see more gene therapy contraction, and the CEO of ...

SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the ...

SyVento says bringing the FlexFactory to Poland makes new therapies available to patients in an efficient and high-quality ...

If I had to buy one share of any biotech with no price restriction, I'd naturally gravitate toward the most successful companies in the industry. However, the exercise becomes more complicated if ...

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the ...